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Novel Roles for Peroxynitrite in 
Angiotensin II and CaMKII Signaling
Chaoming Zhou1,†, Swarna S. Ramaswamy2,‡, Derrick E. Johnson2, Dario A. Vitturi1, 
Franciso J. Schopfer1, Bruce A. Freeman1, Andy Hudmon2 & Edwin S. Levitan1
Ca2+/calmodulin-dependent protein kinase II (CaMKII) oxidation controls excitability and viability. While 
hydrogen peroxide (H2O2) affects Ca2+-activated CaMKII in vitro, Angiotensin II (Ang II)-induced CaMKIIδ 
signaling in cardiomyocytes is Ca2+ independent and requires NADPH oxidase-derived superoxide, but 
not its dismutation product H2O2. To better define the biological regulation of CaMKII activation and 
signaling by Ang II, we evaluated the potential for peroxynitrite (ONOO−) to mediate CaMKII activation 
and downstream Kv4.3 channel mRNA destabilization by Ang II. In vitro experiments show that ONOO− 
oxidizes and modestly activates pure CaMKII in the absence of Ca2+/CaM. Remarkably, this apokinase 
stimulation persists after mutating known oxidation targets (M281, M282, C290), suggesting a novel 
mechanism for increasing baseline Ca2+-independent CaMKII activity. The role of ONOO− in cardiac and 
neuronal responses to Ang II was then tested by scavenging ONOO− and preventing its formation by 
inhibiting nitric oxide synthase. Both treatments blocked Ang II effects on Kv4.3, tyrosine nitration and 
CaMKIIδ oxidation and activation. Together, these data show that ONOO− participates in Ang II-CaMKII 
signaling. The requirement for ONOO− in transducing Ang II signaling identifies ONOO−, which has 
been viewed as a reactive damaging byproduct of superoxide and nitric oxide, as a mediator of GPCR-
CaMKII signaling.
Angiotensin II (Ang II) induces NADPH oxidase-dependent generation of partially reduced oxygen species 
(superoxide, O2.−; hydrogen peroxide, H2O2) to regulate CaMKIIδ activity and promote apoptosis, hypertrophy 
and downregulation of Kv4.3 K+ channels in cardiomyocytes1–6. The latter effect is also produced in neurons, 
possibly to contribute to hypothalamic function7. In vitro studies originally used H2O2, the dismutation product 
of O2.−, to show autoinhibitory domain methionine oxidation (i.e., at M281/282), which sustains CaMKII activ-
ity after Ca2+ is removed and CaM is dissociated (i.e., the enzyme becomes autonomous after Ca2+ priming)1. 
However, Ang II-induced cardiomyocyte hypertrophy and Kv4.3 downregulation are inhibited by superoxide 
dismutase (SOD) but not by catalase, suggesting that O2.−, rather than H2O2, is required for Ang II signal-
ing3–5. Furthermore, Ang II activation of CaMKII in cardiomyocytes is independent of Ca2+ and persists in the 
presence of a CaM inhibitor6, which again contrasts with the in vitro requirement for Ca2+/CaM priming for 
H2O2-mediated generation of autonomous activity1,2. Thus, these findings exclude H2O2 as the mediator of Ang 
II-CaMKII signaling and demonstrate the involvement of O2.−. Similarly, nitric oxide (NO) cannot on its own 
account for Ang II effects as SOD would not be inhibitory. However, O2.− is not a robust oxidizing species and 
does not react with methionine, which is oxidized in CaMKII in response to Ang II1. Therefore, it has been puz-
zling how O2.− mediates Ang II signaling.
One possibility is that O2.− is a precursor for a more reactive species. A candidate reactive species is per-
oxynitrite (ONOO−), which is generated by the diffusion-limited reaction of O2.− and NO8,9. Previously, syn-
thetic ONOO− was shown to react with pure Ca2+/CaM-activated CaMKII in vitro to generate Ca2+-primed 
autonomous activity10,11. For CaMKIIδ , this autonomy requires M281/28211. These studies had limitations, how-
ever, in that they did not (a) measure CaMKII methionine oxidation as only activity was assayed; (b) distin-
guish whether ONOO− or contaminants from its synthesis or spontaneous decomposition account for CaMKII 
responses; (c) determine if CaMKII regulation strictly depends on Ca2+/CaM activation; and (d) address whether 
ONOO− is required for Ang II stimulation of CaMKII in living cells. Therefore, we tested the hypothesis that 
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ONOO− participates in Ang II-induced CaMKII signaling by conducting experiments with purified CaMKII 
and cardiac and neuronal cells.
Results
ONOO−-induced oxidation and activation of purified apoCaMKIIδ. Previous in vitro experiments 
with ONOO− and purified CaMKIIδ reported increased autonomous activity following Ca2+ priming10,11, an 
effect we have reproduced with human CaMKIIδ ONOO− (27.64% ± 1.53%). To extend these studies, the effect 
of ONOO− on CaMKIIδ methionine oxidation was determined and compared with a control consisting of neu-
tral pH decomposition products and potential residual species used in the synthesis of ONOO− (nitrite (NO2−), 
nitrate (NO3−), H2O2). First, recombinant human CaMKIIδ was activated by Ca2+ and CaM in the absence of 
Mg2+ and ATP and then treated with ONOO−. CaMKIIδ M281/282 oxidation state was assayed by immunoblot 
using a site-specific redox antibody. A low signal for M281/282 oxidation was observed for no ONOO− treatment 
and treatment with low concentrations of ONOO− (0.2 and 2 μM), while 20 and 200 μM ONOO− enhanced 
methionine oxidation of CaMKIIδ (Fig. 1A), demonstrating concentration dependent redox modification of 
CaMKII expose to ONOO−. The relatively high concentrations of ONOO− required to induce CaMKIIδ oxida-
tion in vitro are possibly due to the short half-life of ONOO− at neutral pH (~1 second)8,9 and competing reac-
tions of other reaction mixture constituents including residual β -ME present in the purified enzyme preparation. 
To distinguish whether the increase in methionine oxidation was mediated by ONOO−, as opposed to decay 
products or contaminants from synthesis, ONOO− was added to neutral buffer for 2–5 minutes before expos-
ing these products to CaMKIIδ . In contrast to ONOO−, decayed ONOO− (dONOO−) resulted in no CaMKIIδ 
methionine 281/282 oxidation (Fig. 1B). Thus, M281/282 oxidation of CaMKII supports the conclusion that 
ONOO− is a candidate mediator for the modulation of CaMKIIδ activity in cells.
Based on cellular results showing Ca2+-independent CaMKII activation6, we considered whether ONOO− 
could induce CaMKII oxidation in the absence Ca2+ and CaM (i.e., with the apoenzyme). Remarkably, immunob-
lotting showed that CaMKIIδ M281/282 oxidation induced by ONOO− was similar in the presence and absence 
of Ca2+ and CaM (Fig. 1B). While previous studies have largely focused on activity-dependent changes requiring 
priming, these experiments clearly show that ONOO−-induced oxidation does not require Ca2+-CaM binding to 
permit CaMKII oxidation in the autoregulatory domain (ARD).
This result led us to consider that CaMKII oxidation in the absence of Ca2+/CaM may lead to activity inde-
pendent of Ca2+/CaM priming. The effect of ONOO− on CaMKIIδ apoenzyme was therefore determined by 
studying enzymatic activity under low Ca2+ (5 mM EGTA, no CaM) conditions. Despite preventing canoni-
cal activation by omitting CaM and chelating Ca2+, ONOO− (but not dONOO−) induced a small, yet signif-
icant increase in autonomous activity in freshly isolated enzyme (Fig. 2A, n = 5, p < 0.001). We observed 
minimal loss of Ca2+/CaM-dependent activation of CaMKII with ONOO− oxidation, while detecting a ONOO− 
dose-dependent increase in apoenzyme activity (Fig. 2B). Specifically, the increase in apoCaMKIIδ activity at 
concentrations 200 μM and 50 μM of ONOO− is significantly different compared to the reaction without ONOO− 
(p < 0.001 and p < 0.01, respectively). Thus, these experimental data show that ONOO− induces a small, yet 
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Figure 1. ONOO− induces methionine oxidation of purified recombinant CaMKIIδ in vitro. (A) M281/282 
oxidized CaMKII (o-CaMKII) immunoblot showing concentration dependent CaMKIIδ methionine oxidation 
by ONOO−. Numbers are micromolar concentrations. Ca2+ and CaM were present. B. CaMKIIδ M281/282 
oxidation by 200 μM ONOO− (but not 200 μM dONOO−) in the presence and absence of Ca2+ and CaM. 
t-CaMKII, total CaMKII.
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significant increase in apoCaMKIIδ activation without a requirement for Ca2+ and CaM in either the oxidation 
step or to increase basal activity by prior disinhibition of the ARD.
The ONOO−-induced apoCaMKII activity in vitro is less than seen with priming in saturating Ca2+/CaM 
(i.e., ~9-fold difference). Nevertheless, this increase in apoCaMKII activity could be biologically relevant. First, 
because maximal activation is likely never attained in cells, normalization to maximal activity is not a representa-
tion of physiological activity. Second, a small degree of apoCaMKII activation could lead to autophosphoryla-
tion, which would amplify Ca2+-induced activation. Third, basal activation is sustained and so not limited by 
the incidence of action potentials. Therefore, enhanced modest activation could be functionally significant over 
a sustained period of time. Finally, increased basal activity plus the enhanced autonomous activity previously 
reported following Ca2+/CaM priming10,11 could interact to contribute to ONOO−-induced signaling by CaMKII. 
Therefore, we explored the molecular basis of ONOO− action on apoCaMKII.
Direct ONOO− activation of CaMKII is not mediated by M281, M282 or C290. Because prior 
experiments demonstrated roles for M281/282 and C290 in facilitation of Ca2+-CaM-primed CaMKII activity by 
H2O2, ONOO− and NO1,10–12, we examined whether these residues are required for the ONOO− effect on wild-
type human apoCaMKIIδ activity using double (M281V/M282V) and triple (M281V/M282V/C290V) mutants 
of these known oxidation sites in the ARD. To minimize complications with CaMKIIδ oxidation during storage 
and freezing, we expressed and purified the wildtype, double and triple mutants simultaneously and used fresh 
non-frozen enzyme to perform the comparisons.
In the absence of oxidizers, wildtype and the double mutant displayed similar apoCaMKII activity. However, 
the triple mutant displayed enhanced apoCaMKII activity (Fig. 3, black bars), suggesting that the triple mutant 
“loosens” the ARD compared to wildtype and the double mutant of CaMKIIδ . More importantly, ONOO− acti-
vation of CaMKII was similar for wildtype and the double and triple mutants (Fig. 3, light gray bars). Therefore, 
previously identified ARD oxidation sites that are important for regulating Ca2+/CaM-primed CaMKII are not 
required for ONOO−-induced activation of apoCaMKII.
This surprising result led us to examine the effect of H2O2 (Fig. 3, dark gray bars), which was originally 
used to demonstrate regulation of Ca2+/CaM-primed CaMKII by methionine oxidation1. When the effects of 
Figure 2. ONOO− induced activation in CAMKIIδ. (A) Percentage of autonomous activity of CaMKIIδ in 
the presence and absence of 200 μM ONOO−. The percentage was calculated from activity of apoenzyme in the 
presence of EGTA in comparison to maximal activity in the presence of Ca2+/CaM. One-way ANOVA using 
Dunnett’s test in comparison to control (No ONOO−); ***p < 0.001 (n = 5). (B) Kinase activity of CaMKIIδ in 
the presence of Ca2+/CaM (Ca2+/CaM-dependent activity) and EGTA (Ca2+/CaM independent activity) with 
increasing concentrations of ONOO− and dONOO−. Activity is represented as specific activity, in μmol min−1 
mg−1. Data represent mean values ± s.e.m from 3 experiments. Note the differences in scale for the two y-axes. 
One-way ANOVA using Dunnett’s post-test compared with control (No ONOO−); **p < 0.01; ***p < 0.001.
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ONOO− and H2O2 were compared in side-by-side studies, we observed that, as described previously, H2O2 did 
not induce apoCaMKII activity with the wildtype enzyme. In contrast, the triple mutant did appear susceptible 
to a statistically significant increase in H2O2 activation compared to wildtype. However, the autonomous activity 
generated by H2O2 did not reach the same level as seen by ONOO− even though a 15-fold higher concentration 
was used (3 mM) and H2O2 is much more stable than ONOO−, which decomposes in seconds. Therefore, the 
novel Ca2+-independent increase in apoenzyme activity described here must involve a residue that has not been 
previously implicated in redox regulation of Ca2+/CaM-primed CaMKII. Apparently, this site is readily oxidized 
by ONOO−, but less reactive H2O2 is not effective unless the enzyme is partially activated by mutagenesis of the 
ARD.
Ang II induces ONOO− signaling in cardiac and neuronal cells. Contrary to prior reports, the above 
in vitro studies using human CaMKIIδ are consistent with the Ca2+-independent activation described previously 
in cardiomyocytes6 and so support the hypothesis that ONOO− may contribute to Ang II-induced activation of 
CaMKII in cells, at least in part through Ca2+-independent modifications. Thus, to examine the mechanisms 
underlying Ang-II redox signaling, we turned to the Ang II-induced CaMKII activation shown previously to 
downregulate the Kv4.3 K+ channel, which is produced by mRNA destabilization induced by AUF1 protein bind-
ing to the Kv4.3 3′ untranslated region (3′ UTR) in response to CaMKII phosphorylation2,5,13. Using the Kv4.3 
3′ UTR luciferase reporter construct5, we evaluated upstream redox signaling regulating Kv4.3 mRNA stability. 
Although the turnover of luciferase attenuates the effect on native mRNA, internal normalization ensures that 
results are quantitative and reproducible and are not impacted by presence of native Kv4.3 mRNA. Therefore, the 
reporter was transfected into cultured neonatal rat ventricular cardiomyocytes (CM), cardiac H9C2 cells, neu-
ronal CATH.a and Neuro-2a cells. In both cardiac and neuronal backgrounds, reporter activity was sensitive to 
100 nM Ang II (Fig. 4A, open bars).
Because this suggests shared signaling, the four cell systems were also used to test whether the Ang II-Kv4.3 
effect requires ONOO−. First, the impact of the ONOO− scavenger FeTPPS (5,10,15,20-Tetrakis(4-sulfonat
ophenyl) porphyrinato Iron (III)) was determined. 50–100 μM FeTPPS blocked the Ang II-induced reporter 
responses, increased the baseline reporter signal and altered cell morphology, suggesting possible toxicity. To 
address this limitation, the ONOO− scavenger UA was used10. UA did not affect baseline values or morphology, 
but blocked the Ang II responses in the four cell systems (Fig. 4A). The four cell systems were then used to test 
whether the Ang II-Kv4.3 effect requires NO, which reacts with O2.− to yield ONOO−14. Specifically, the effect of 
the NO synthesis inhibitor L-NAME was compared to its inactive isomer D-NAME. In all four cases, L-NAME, 
but not D-NAME, abolished the Ang II-Kv4.3 response (Fig. 4B). The requirement for O2.− for this signaling7 and 
the above effect of scavenging ONOO− with UA show that NO is not sufficient for this Ang II effect. Instead, these 
results suggest a requirement for ONOO− in cardiac and neuronal cell Ang II-Kv4.3 mRNA responses.
ONOO− becomes protonated under physiological conditions to peroxynitrous acid (ONOOH), which in turn 
undergoes homolytic scission to the oxidizing species hydroxyl radical (.OH) and the nitrating species nitrogen 
dioxide (.NO2). An index of ONOO− generation and signaling is tyrosine nitration, which is induced by .NO2 
and not the individual reactions of O2.−, H2O2 or NO. Therefore, to independently test whether Ang II signals via 
Figure 3. Direct ONOO− activation of apoCaMKII is not mediated by M281/282 or C290. Ca2+/CaM-
independent activity is plotted as a percentage of the Ca2+/CaM dependent activity for WT, double and triple 
oxidation mutants. The % autonomy was calculated for the wildtype, double (MM281,282VV) and triple 
(MM281,282VV; C290V) mutants in the following conditions: no oxidation (None); with 200 μM ONOO− and 
with 3 mM H2O2. One-way ANOVA using Dunnett’s test compared to controls- **p < 0.01; ***p < 0.001- 
significance of difference upon oxidation compared to no oxidation; ###p < 0.001- significance of mutation 
compared to wildtype.
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ONOO−, tyrosine nitration was assayed by immunoblot from H9C2 cell extracts by quantifying the formation 
of nitrotyrosine (NO2-Tyr) adducts. In these experiments, the strongest signal was from a 53 kD protein, which 
may be derived from desmin, a key target of tyrosine nitration in the heart15. Consistent with the generation and 
action of ONOO−, not only did Ang II induce tyrosine nitration in H9c2 cells but most importantly, this effect 
was abolished by either inhibition of NO synthesis with L-NAME or by the ONOO− scavenger UA (Fig. 5). These 
results independently support the conclusion that Ang II promotes cellular ONOO− generation.
It is known that Ang II induces oxidation of CaMKIIδ in cardiomyocytes, which has been measured by 
immunoblot with an antibody that detects M281/282 oxidation1,2. Therefore, cardiomyocytes were treated with 
L-NAME, D-NAME and UA and immunoprecipitated CaMKIIδ was probed for M281/282 oxidation. As can 
be seen in Fig. 6, disrupting ONOO− signaling inhibited oxidation of CaMKII. Thus, these experiments further 
establish that Ang II induces ONOO−-mediated protein oxidation.
Ang II-induced autophosphorylation of CaMKII requires ONOO−. Ang II regulation of Kv4.3 mRNA 
stability requires a delayed prolonged phase of CaMKII signaling2. To test whether ONOO− induces this effect, 
cardiomyocytes were treated for 150 min with Ang II, D-NAME, L-NAME, and/or UA, then cell extracts were 
generated and endogenous CaMKIIδ was immunoprecipitated. The effect on Ang II-induced CaMKIIδ enzymatic 
activation was then measured by assaying T287 autophosphorylation of CaMKIIδ by immunoblot, an estab-
lished method that is sensitive enough to be applied to primary cultures containing thousands of cardiomyocytes. 
Consistent with the above results, CaMKIIδ autophosphorylation induced by Ang II was blocked by L-NAME, 
but not D-NAME (Fig. 7A). Furthermore, UA also inhibited Ang II-induced CaMKIIδ autophosphorylation 
(Fig. 7B), affirming that OONO− is required for Ang II-induced CaMKII activation.
Discussion
This study was motivated by a puzzle regarding the role of Ca2+ and redox signaling underlying Ang II action. 
Hypertrophy and Kv4.3 studies have established that O2.−, but not H2O2, is required for Ang II signaling3–5. 
Furthermore, CaMKII is required for Ang II-induced effects (e.g. on Kv4.3 expression and apoptosis), which 
are correlated with CaMKII methionine oxidation1,2. However, oxidative stimulation of CaMKII was thought to 
require priming by Ca2+, while Ang II can activate CaMKII independently of Ca2+ 6. Furthermore, O2.− is a weak 
oxidizer of methionine. Therefore, we wondered how Ang II acts via O2.− and independently of H2O2 and Ca2+ to 
stimulate CaMKII-induced Kv4.3 downregulation. Purified enzyme and cell-based CaMKIIδ activation studies 
reported herein resolve this quandary by showing that ONOO− is necessary and sufficient for CaMKII activation 
by Ang II. Specifically, the involvement of O2.− without dismutation to H2O2, is now understood in terms of the 
requirement of O2.− as a precursor of ONOO− generation. Therefore, the identification of ONOO− as a signaling 
intermediate clarifies how Ang II activates CaMKII to control Kv4.3 expression.
Figure 4. ONOO− is required for Ang II-Kv4.3 signaling in cardiac and neural cells. (A) Kv4.3 luciferase 
reporter response to 100 nM Ang II in cardiomyocytes (CM), H9C2 cells, Catha.a cells and Neuro-2A cells 
in the presence or absence of 300 μM UA. Each bars represent mean values ± s.e.m. from 4–9 experiments. 
Ang II alone in each cell type, p < 0.001. (B) L-NAME, but not D-NAME, inhibits the Ang II-Kv4.3 signaling 
in cardiac and neural cells (cardiomyocytes (CM), H9C2 cells, CATH.a cells, and N2A cells). Data are mean 
values ± s.e.m. from 4–7 luciferase reporter experiments. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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Previous experiments have implicated methionines 281 and 282 and cysteine 290 in promoting autonomy of 
Ca2+-primed CaMKII1,10–12, but the current study shows that another mechanism operates independently of these 
residues to increase apoCaMKIIδ activity in response to ONOO−. This novel activation mechanism is a fraction 
of the activity compared to canonical Ca2+/CaM stimulation and smaller than ONOO−-induced autonomy fol-
lowing Ca2+/CaM priming. However, the relative impact of this change in basal activity induced by ONOO− may 
be more significant than indicated by percentage of maximal activation measured in vitro. First, because bulk 
Ca2+ in cells never reaches levels required to saturate CaMKII under conditions of limiting free [CaM], autophos-
phorylation within the CaM-target domain of CaMKII can prevent CaM activation, and CaM itself is sensitive to 
oxidation, which renders it unable to activate CaMKII16–19, CaMKII signaling is likely submaximal under physio-
logical conditions. The extent of ONOO− activation may also be underestimated because the purified kinase may 
become oxidized during isolation and storage. In fact, our experience with the wildtype CaMKIIδ was that as the 
enzyme aged in the − 80 °C freezer, the ability to induce ONOO−-induced apoenzyme activity diminished, which 
is why for the comparison to mutants we purified all of the material together to avoid aging artifacts. Finally, 
increased basal activation may synergize with conventional effects of Ca2+ and the Ca2+-dependent effects of 
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ONOO− and NO10–12,20. This may be particularly important in the context of prolonged Ang II signaling, which 
is important for controlling hypertrophy, channel expression and apoptosis. Thus, the apparently small change in 
apoCaMKII activity may be significant in living cells.
Ang II-induced activation and oxidation of CaMKII is biphasic with long lasting activation becoming evident 
after a delay of hours following transient activation2. Therefore, it is likely that ONOO−, which mediates Ang II 
action but is chemically unstable, is generated continuously to support delayed CaMKII activation during this 
period. Because prolonged Ang II action in cardiomyocytes requires NADPH oxidase-24, but other cells can 
instead utilize NADPH oxidase-4 to mediate Ang II effects21, it will be of interest to identify the source of O2.− for 
synthesis of ONOO−. Likewise, the source of NO remains to be determined. Of interest, all three NOS isoforms 
are present in cardiomyocytes, but NOS1 is uniquely upregulated by Ang II with a delay comparable to the second 
phase of CaMKII activation studied here2,22. Regardless of the sources of O2.− and NO, the current results support 
the concept that Ca2+-independent and previously known Ca2+-dependent effects of ONOO− act in concert to 
promote CaMKII activation in vivo.
These data reveal a novel signaling function for ONOO−. ONOO− is typically viewed as a pathogenic mediator 
because ONOO− generation (a) indicates the diversion of NO signaling away from guanylate cyclase activation 
and (b) yields potent oxidizing and nitrating species. Thus, the reaction of ONOO− with proteins often inactivates 
or impairs function9. Therefore, the demonstration that ONOO− can act as an intermediate in G-protein coupled 
receptor (GPCR) signaling by activating a functionally-significant downstream kinase defines a regulated and 
central biological action for this reactive species. Indeed, our results suggest that other receptor-NADPH oxidase 
effects that have been attributed to O2.− or its dismutation product H2O2 may in fact be mediated by ONOO−.
This insight has implications for organ physiology, pharmacology and pathology. Previously, Ang II-NADPH 
oxidase signaling was primarily attributed to the actions of O2.− and its dismutation product H2O2. Because Ang 
II and CaMKII oxidation are associated with cardiac pathology23,24 and ONOO− is required for Ang II-induced 
CaMKII activation, suppressing ONOO− generation and steady state concentrations in the heart may be of clin-
ical benefit. It will also be interesting to determine whether this novel mechanism contributes to the clinical effi-
cacy of Ang II AT1 receptor blockers (ARBs) and ACE (angiotensin converting enzyme) inhibitors. Furthermore, 
because Ang II-NADPH oxidase-Kv channel signaling occurs in neurons7,25 and ONOO− is required for Ang 
II-Kv channel signaling in neuronal cells (Fig. 4), ONOO− oxidation of CaMKII may be of significance for many 
organ and tissue functions.
Methods
All experiments were performed in accordance with relevant guidelines and regulations. Culture, 
transfection and treatment of cardiomyocytes and cell lines. Neonatal Sprague-Dawley rat ventricular cardiomyo-
cyte cultures were generated by a protocol approved by the University of Pittsburgh Institutional Animal Care 
and Use Committee. Culture, transfection and Ang II treatments in serum-free medium (which yields nonbeating 
cardiomyocytes) were performed as previously described2,5. CATH.a cells were plated on 24 well plate with density 
of 1.25 × 105 in RPMI-1640 medium (Invitrogen) plus 8% horse serum and 4% FBS. The following day cells were 
transfected using Lipofectamine Plus reagent (Invitrogen) with 0.5 μg DNA per well following the manufacturer’s 
protocol. After 4 hours, the medium was replaced with the fresh medium supplemented with 1 mM dibutryl-cAMP. 
Two days later, cells were treated with vehicle or Ang II for 6 hours in serum free medium. Neuro-2A cells were 
plated on 24 well plate at a density of 2 × 105 per well in MEM (Invitrogen) with 10% FBS, 1 mM sodium pyru-
vate and 25 mM HEPES, pH 7.5. The following day, the cells were transfected using FuGENE HD Transfection 
Reagent (Promega) at a 4:1 ratio to DNA (0.75 μg per well) following the manufacturer’s protocol overnight. Then 
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the medium was replaced with MEM 1% FBS for two days. Cells were then treated with vehicle or Ang II for 
6 hours in serum free medium. H9C2 cells were plated on 24 well plate with density of 3.75 × 104 per well in DMEM 
(Invitrogen) with 10% FBS. Cells were cultured 4 days and then were transfected using same method as used with 
Neuro-2A cells. The following day the medium was replaced with serum free medium and treated with vehicle or 
with Ang II for 24 hours.
Inhibitors were purchased from Sigma-Aldrich. 100 μM L-NAME (NG-Nitro-L-arginine methyl ester), 
D-NAME and 300 μM uric acid (UA) were applied for 30 minutes prior to treatment with 100 nM Ang II.
Immunoprecipitation (IP), SDS-PAGE and immunoblotting of endogenous CaMKII. IP and SDS-PAGE fol-
lowed published protocols4. Membranes were incubated overnight at 4 °C with mouse monoclonal anti-T286 
phospho-CaMKII antibody (1:500) (Santa Cruz Biotechnology) and rabbit polyclonal anti-total CaMKII (pan) 
(1:1000) (Cell Signaling) or with rabbit polyclonal anti-oxidized M281/282 CaMKII antibody (1:2000) (Millipore) 
and mouse monoclonal anti-total CaMKII antibody (1:1000) (Abcam). Membranes were washed 4 times 5 min 
with PBST and then incubated 1 hour in room temperature with IRDye 800CW Gt Anti-Rabbit IgG (H + L) anti-
body and IRDye 680LT Anti-Mouse IgG (H ± L) antibody (1:15,000) (Li-COR Bioscience). Infrared fluorescence 
was detected by the Odyssey Imaging System.
Nitrotyrosine detection. H9C2 cells treated with vehicle or Ang II (100 nM) in the presence or absence 
of L-NAME or UA as described above. Cells were harvested in lysis buffer (CelLytic M, Sigma) and proteins 
resolved by SDS-PAGE. Nitrotyrosine was detected by immunoblotting after overnight incubation with a 
1:1000 dilution of a monoclonal antibody (clone 1A6, Millipore), followed by incubation with an Horse radish 
peroxidase-conjugated secondary antibody and chemiluminescent detection using the Immun-Star substrate 
system (BioRad). Densitometric analysis was performed using ImageJ software (NIH) and the resulting data was 
normalized to β -actin levels. Statistical evaluation was performed by one-way ANOVA with Tukey’s multiple 
comparisons test.
Peroxynitrite-induced oxidation of recombinant CaMKIIδ in vitro. Peroxynitrite was synthesized from nitrite 
and hydrogen peroxide using a quenched-flow reactor as described previously14. Excess hydrogen peroxide was 
removed using manganese dioxide and the concentration of the peroxynitrite solution was determined from its 
absorbance at 302 nm (ε = 1670 M −1 cm−1) in 500 mM NaOH.
Recombinant human CaMKIIδ (EMD Millipore or purified as described previously26,27 was used for 
ONOO−-induced CaMKII oxidation. CaMKII oxidation in the presence of Ca2+/CaM was carried out in a reac-
tion mixture containing 100 mM Tris, pH 7.0, 0.3–1 μM CaMKIIδ , with 6–10 μM of CaM and 0.5 mM of Ca2+, 
or in the absence of Ca2+/CaM and presence of 5 mM EGTA. ONOO− was added last to the side of the reaction 
tube and rapidly mixed with the kinase by vortexing. For control reactions using the decayed ONOO− product, 
the reaction was preincubated in the Tris pH 7.0 buffer 2–5 minutes to induce decomposition before addition of 
kinase. The ability of 100 mM Tris pH 7.0 to maintain the reaction pH was experimentally verified.
For activity measurements, 1 μM hCaMKIIδ wild type and mutants were oxidized as described above in 
200 uM ONOO− or 3 mM H2O2. Then 10–100 nM of the kinase was added to 50 mM PIPES, pH 7.0, 100 mM 
NaCl, 10 mM MgCl2, 100 μM ATP and 120 μCi/ml [γ -32P]ATP, 200 μM AC-2 peptide (KKALRRQETVDAL), and 
either 1 mM CaCl2 and 10 μM CaM for maximal activation as described previously26,27 or 5 mM EGTA (-Ca2+/
CaM) for measuring activity independent of Ca2+/CaM. The reaction proceeded at 30 °C for 3 minutes (within 
the linear range) before spotting onto P81 filter paper and thoroughly washed in 75 mM phosphoric acid. The 
Ca2+/CaM independent activity was compared between the mutants and across the oxidative agents, as specific 
autonomous activity (Ca2+/CaM-independent activity divided by Ca2+/CaM-dependent activity). For activation 
assays comparing mutant proteins, CaMKII wild type and mutants were expressed in Hi5 cells using baculovirus. 
Hi5 cells expressing wildtype, double mutant (MM281, 282VV) and the triple mutant (MM281,282VV; C290V) 
were collected by centrifugation. The cells were lysed using a microfluidizer in buffer containing 50 mM HEPES, 
100mM NaCl, 0.1 mM EDTA, and protease inhibitor with 500μM AEBSF HCl, 300 nM Aprotinin, 6 μM E-64, 
20 μM Leupeptin. The lysate was then spun at 30000 rpm for 30 min and the supernatant was used to load onto 
a NiNTA resin. After binding, the resin was washed and the protein was eluted using buffer containing 50mM 
HEPES, 100 mM NaCl, 0.1 mM EDTA, 25 mM Imidazole. The elute was then passed through HiTrap desalting 
column and exchanged to buffer containing 50 mM Tris, 100 mM NaCl, 0.1 mM EDTA. The protein was quanti-
fied and 1 μM concentration of the protein was used for experiments as described above.
For M281/282 oxidation blots, 5–10 minutes after treatment with ONOO− or dONOO− at room tempera-
ture, samples were boiled in SDS-PAGE loading buffer and separated on a 8.5% acrylamide or 10% NuPage gel, 
which was transferred onto a Trans-Blot Transfer Medium Pure Nitrocellulose Membrane (0.2 μm) (Bio-Rad). 
Following blocking with bovine serum albumin or milk, the membrane was incubated overnight at 4 °C with 
anti-rabbit polyclonal against M281/282 oxidized-CaMKII antibody (1:2000) (Millipore) and anti-goat poly-
clonal antibody against total CaMKIIδ (Santa Cruz Biotechnology). Membranes were washed for 5 minutes 4 
times with PBST or TBSt and then incubated 1 hour in room temperature with IRDye 800CW Gt Anti-goat IgG 
(H+ L) antibody and IRDye 680LT Anti-rabbit IgG (H ± L) antibody (1:15,000) (Li-COR Bioscience). Infrared 
fluorescence was detected by Odyssey Imaging System.
Statistics. Data are quantified as the mean ± standard error of the mean (s.e.m.). Statistical significance was 
determined by Student’s t-test for experiments with two experimental conditions and one-way ANOVA followed 
by Dunnett’s, Bonferroni or Tukey’s post-test for experiments with more than two experimental conditions.
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